THE POTENCY AND CLINICAL EFFICACY OF AROMATASE INHIBITORS IN BREAST CANCER HORMONAL THERAPY

Q: How can I download an article?

To download an article from SID, first log in to the site, search for the article title, and click on the 'Download Article' option.

Q: How can I download an ISI article?

To download an ISI article on SID, enter the keyword or article title in the search bar, view the relevant results, click on the desired article, and select the 'Download Article' option.

Q: How can I access the SID database?

To access the SID database, visit SID.ir, create an account, and log in to access scientific resources.

Q: Is downloading articles from SID free?

Some articles on SID are available for free, while others require payment. Details are specified on the article's page.

NAJAFI SAFA

مرکز اطلاعات علمی Scientific Information Database (SID) - Trusted Source for Research and Academic Resources

Journal Paper

Paper Information

Journal: Iranian Journal of Breast Diseases Year:2010 | Volume:3 | Issue:1-2 Page(s): 55-68

Download Full-Text

Persian Verion

View:

1,637

Download:

Cites:

Information Journal Paper

Title

THE POTENCY AND CLINICAL EFFICACY OF AROMATASE INHIBITORS IN BREAST CANCER HORMONAL THERAPY

Author(s)

NAJAFI SAFA | Issue Writer Certificate

Keywords

ANASTROZOLEQ4

AROMATASE INHIBITORQ2

BREAST CANCERQ4

ESTROGENQ4

EXEMESTANEQ4

LETROZOLEQ4

Abstract

Background: The strategy of using ESTROGEN suppression to treat BREAST CANCER led to the development of AROMATASE INHIBITORs, including the third-generation nonsteroidal compounds ANASTROZOLE and LETROZOLE, and the steroidal compound EXEMESTANE.Material and Methods: AROMATASE INHIBITORs potently inhibit aromatase activity and also suppress ESTROGEN levels in plasma and tissue. In clinical studies in postmenopausal women with BREAST CANCER, third-generation AROMATASE INHIBITORs were shown superior to tamoxifen for the treatment of metastatic disease. Studies of adjuvant therapy with AROMATASE INHIBITORs include (i) head-to-head studies of 5 years of the AROMATASE INHIBITOR versus 5 years of tamoxifen monotherapy; (ii) sequential therapy of 2–3 years of tamoxifen followed by an AROMATASE INHIBITOR (or the opposite sequence) versus 5 years of tamoxifen onotherapy; (iii) extended therapy with an AROMATASE INHIBITOR after 5 years of tamoxifen; and (iv) sequential therapy with an AROMATASE INHIBITOR versus AROMATASE INHIBITOR monotherapy.Results and Conclusion: Recent results from the Arimidex, Tamoxifen, Alone or in Combination and Breast International Group 1-98 trials advocate using an AROMATASE INHIBITOR upfront. This article examines the clinical data with AROMATASE INHIBITORs, following a brief summary of their pharmacology.

Cites

No record.

References

No record.

Cite

APA: Copy

NAJAFI, SAFA. (2010). THE POTENCY AND CLINICAL EFFICACY OF AROMATASE INHIBITORS IN BREAST CANCER HORMONAL THERAPY. IRANIAN QUARTERLY JOURNAL OF BREAST DISEASE, 3(1-2), 55-68. SID. https://sid.ir/paper/144723/en

Vancouver: Copy

NAJAFI SAFA. THE POTENCY AND CLINICAL EFFICACY OF AROMATASE INHIBITORS IN BREAST CANCER HORMONAL THERAPY. IRANIAN QUARTERLY JOURNAL OF BREAST DISEASE[Internet]. 2010;3(1-2):55-68. Available from: https://sid.ir/paper/144723/en

IEEE: Copy

SAFA NAJAFI, “THE POTENCY AND CLINICAL EFFICACY OF AROMATASE INHIBITORS IN BREAST CANCER HORMONAL THERAPY,” IRANIAN QUARTERLY JOURNAL OF BREAST DISEASE, vol. 3, no. 1-2, pp. 55–68, 2010, [Online]. Available: https://sid.ir/paper/144723/en

Related Journal Papers